NOI - MALDI Biotyper Sirius CA System
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), Clinical Center (CC), on behalf of its Department of Laboratory Medicine (DLM), has issued a Notice of Intent (NOI) to award a Firm-Fixed-Price (FFP) sole source purchase order to Bruker Scientific, LLC for a MALDI Biotyper Sirius CA System. This system is critical for the rapid and accurate identification of microorganisms from clinical cultures. Capability statements from interested parties are due by April 27, 2026, at 4:00 PM EST.
Requirement
The DLM's Microbiology Service requires the MALDI Biotyper Sirius CA System to support the identification of bacteria, fungi, and mycobacteria from clinical cultures. This system is a direct successor to the currently utilized Bruker MALDI Biotyper Smart System, which is approaching its end-of-service life (March 2027) and experiencing increased maintenance needs.
Sole Source Rationale
The NIH intends to award this contract to Bruker Scientific, LLC due to the unique compatibility of the Sirius CA System with existing laboratory operations. Transitioning to a different manufacturer's platform would necessitate substantial validation and verification of clinical assays, retraining of personnel, and modification of laboratory processes. This would lead to significant duplication of effort, increased costs, potential delays in diagnostic testing, and disruption to mission-critical clinical services. Market research confirmed that no alternative vendor could provide a system compatible with the existing Bruker platform without these adverse impacts. The estimated cost for this acquisition is $314,207.71.
Contract & Timeline
- Type: Firm-Fixed-Price Sole Source Purchase Order
- Intended Awardee: Bruker Scientific, LLC
- Estimated Value: $314,207.71
- Product Service Code: 6640 (Laboratory Equipment And Supplies)
- Response Due: April 27, 2026, at 4:00 PM EST
- Published: April 17, 2026
Interested Parties
This is a Notice of Intent, not a request for quotation. Interested organizations may submit a capability statement demonstrating their ability to meet this requirement. Submissions should include:
- Relevant experience providing similar diagnostic testing equipment.
- Technical capability to support MALDI Biotyper Sirius CA System or equivalent systems.
- Business size classification under NAICS 334516.
Statements must be submitted electronically to Gregory Noland at gregory.noland@nih.gov.
Additional Notes
This acquisition is conducted under FAR Part 13 – Simplified Acquisition Procedures and FAR 13.106-1(b)(1). The Government reserves the right not to compete this requirement, and the determination to proceed with a sole source award is at its sole discretion.